ArticleJournal of nephrology2025
Longitudinal associations between iron status and patient-reported outcomes in incident dialysis patients: a DOMESTICO substudy.
Article in Journal of nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMore liberal use of iron therapy is favored in dialysis patients based on lower erythropoietin need and clinical outcomes. However, it remains unclear whether higher iron stores are associated with better patient-reported outcomes. We assessed the longitudinal associations of ferritin and transferrin saturation (TSAT) levels with patient-reported outcomes in incident dialysis patients.
methodsThis prospective cohort study included incident dialysis patients who had completed at least one patient-reported outcome questionnaire and had undergone a laboratory assessment (e.g., ferritin, transferrin saturation, hemoglobin) within the first year of dialysis. The primary outcome was health-related quality of life (HRQoL), measured using the 12-Item Short Form (SF-12) survey. Secondary outcomes were the presence of anemia-related symptoms, measured using the Dialysis Symptom Index. We used sequential conditional mean models to adjust for baseline and time-varying confounding.
resultsWe included 1069 incident dialysis patients, of whom 76% initiated hemodialysis. The mean (SD) age was 64.0 (14.2) years and 34% were female. Over a 1-year follow-up, patients with ferritin levels < 200, > 500 - 700, and > 700 ng/mL did not have a significantly different HRQoL compared to those with levels between 200 - 500 ng/mL, chosen as reference. Similarly, patients with TSAT levels < 20 or ≥ 40% did not have a significantly different HRQoL compared to those with levels between 20 - 39%. No significant differences were found in the odds of experiencing fatigue, shortness of breath, muscle cramps or restless legs between the ferritin and TSAT groups.
conclusionDifferences in iron status parameters were not associated with differences in patient-reported outcomes during the first year of dialysis. Our findings therefore suggest that decisions on iron therapy should be guided by target hemoglobin levels and clinical outcomes in dialysis patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.